Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation : An Observational Cohort Study. / Bonde, Anders Nissen; Lip, Gregory Y H; Kamper, Anne-Lise; Fosbøl, Emil L; Staerk, Laila; Carlson, Nicholas; Torp-Pedersen, Christian; Gislason, Gunnar; Olesen, Jonas Bjerring.

I: Stroke, Bind 47, Nr. 11, 2016, s. 2707-2713.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Bonde, AN, Lip, GYH, Kamper, A-L, Fosbøl, EL, Staerk, L, Carlson, N, Torp-Pedersen, C, Gislason, G & Olesen, JB 2016, 'Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study', Stroke, bind 47, nr. 11, s. 2707-2713. https://doi.org/10.1161/STROKEAHA.116.014422

APA

Bonde, A. N., Lip, G. Y. H., Kamper, A-L., Fosbøl, E. L., Staerk, L., Carlson, N., Torp-Pedersen, C., Gislason, G., & Olesen, J. B. (2016). Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study. Stroke, 47(11), 2707-2713. https://doi.org/10.1161/STROKEAHA.116.014422

Vancouver

Bonde AN, Lip GYH, Kamper A-L, Fosbøl EL, Staerk L, Carlson N o.a. Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study. Stroke. 2016;47(11):2707-2713. https://doi.org/10.1161/STROKEAHA.116.014422

Author

Bonde, Anders Nissen ; Lip, Gregory Y H ; Kamper, Anne-Lise ; Fosbøl, Emil L ; Staerk, Laila ; Carlson, Nicholas ; Torp-Pedersen, Christian ; Gislason, Gunnar ; Olesen, Jonas Bjerring. / Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation : An Observational Cohort Study. I: Stroke. 2016 ; Bind 47, Nr. 11. s. 2707-2713.

Bibtex

@article{50ecab46f40a4fbe94f634b08c2b15ab,
title = "Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study",
abstract = "BACKGROUND AND PURPOSE: We sought to determine the risk of stroke/thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups.METHODS: We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR.RESULTS: A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke/thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97-1.56), 1.26 (95% CI, 1.14-1.40), 1.18 (95% CI, 1.07-1.31), 1.11 (95% CI, 0.87-1.42), 2.01 (95% CI, 1.14-3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m(2), respectively. Use of warfarin was associated with lower risk of stroke/thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m(2); hazard ratios 0.57 (95% CI, 0.43-0.76), 0.57 (95% CI, 0.51-0.64), 0.48 (95% CI, 0.44-0.54), 0.60 (95% CI, 0.45-0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 1.73 m(2), respectively. Use of warfarin was not associated with lower risk of stroke/thromboembolism in patients with eGFR<15 mL/min per 1.73 m(2); hazard ratio 1.18 (95% CI, 0.58-2.40).CONCLUSIONS: In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR≥15 mL/min per 1.73 m(2).",
author = "Bonde, {Anders Nissen} and Lip, {Gregory Y H} and Anne-Lise Kamper and Fosb{\o}l, {Emil L} and Laila Staerk and Nicholas Carlson and Christian Torp-Pedersen and Gunnar Gislason and Olesen, {Jonas Bjerring}",
note = "{\textcopyright} 2016 American Heart Association, Inc.",
year = "2016",
doi = "10.1161/STROKEAHA.116.014422",
language = "English",
volume = "47",
pages = "2707--2713",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams & Wilkins",
number = "11",

}

RIS

TY - JOUR

T1 - Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation

T2 - An Observational Cohort Study

AU - Bonde, Anders Nissen

AU - Lip, Gregory Y H

AU - Kamper, Anne-Lise

AU - Fosbøl, Emil L

AU - Staerk, Laila

AU - Carlson, Nicholas

AU - Torp-Pedersen, Christian

AU - Gislason, Gunnar

AU - Olesen, Jonas Bjerring

N1 - © 2016 American Heart Association, Inc.

PY - 2016

Y1 - 2016

N2 - BACKGROUND AND PURPOSE: We sought to determine the risk of stroke/thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups.METHODS: We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR.RESULTS: A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke/thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97-1.56), 1.26 (95% CI, 1.14-1.40), 1.18 (95% CI, 1.07-1.31), 1.11 (95% CI, 0.87-1.42), 2.01 (95% CI, 1.14-3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m(2), respectively. Use of warfarin was associated with lower risk of stroke/thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m(2); hazard ratios 0.57 (95% CI, 0.43-0.76), 0.57 (95% CI, 0.51-0.64), 0.48 (95% CI, 0.44-0.54), 0.60 (95% CI, 0.45-0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 1.73 m(2), respectively. Use of warfarin was not associated with lower risk of stroke/thromboembolism in patients with eGFR<15 mL/min per 1.73 m(2); hazard ratio 1.18 (95% CI, 0.58-2.40).CONCLUSIONS: In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR≥15 mL/min per 1.73 m(2).

AB - BACKGROUND AND PURPOSE: We sought to determine the risk of stroke/thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups.METHODS: We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR.RESULTS: A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke/thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97-1.56), 1.26 (95% CI, 1.14-1.40), 1.18 (95% CI, 1.07-1.31), 1.11 (95% CI, 0.87-1.42), 2.01 (95% CI, 1.14-3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m(2), respectively. Use of warfarin was associated with lower risk of stroke/thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m(2); hazard ratios 0.57 (95% CI, 0.43-0.76), 0.57 (95% CI, 0.51-0.64), 0.48 (95% CI, 0.44-0.54), 0.60 (95% CI, 0.45-0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 1.73 m(2), respectively. Use of warfarin was not associated with lower risk of stroke/thromboembolism in patients with eGFR<15 mL/min per 1.73 m(2); hazard ratio 1.18 (95% CI, 0.58-2.40).CONCLUSIONS: In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR≥15 mL/min per 1.73 m(2).

U2 - 10.1161/STROKEAHA.116.014422

DO - 10.1161/STROKEAHA.116.014422

M3 - Journal article

C2 - 27758943

VL - 47

SP - 2707

EP - 2713

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 11

ER -

ID: 177533154